Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
- Author:
Makoto NISHIO
1
;
Dong Wan KIM
;
Yi Long WU
;
Kazuhiko NAKAGAWA
;
Benjamin J SOLOMON
;
Alice T SHAW
;
Satoshi HASHIGAKI
;
Emiko OHKI
;
Tiziana USARI
;
Jolanda PAOLINI
;
Anna POLLI
;
Keith D WILNER
;
Tony MOK
Author Information
- Publication Type:Original Article
- Keywords: Asia; Carboplatin; Cisplatin; Crizotinib; Non-small cell lung carcinoma; Pemetrexed
- MeSH: Asia; Asian Continental Ancestry Group*; Carboplatin; Carcinoma, Non-Small-Cell Lung*; Cisplatin; Continental Population Groups; Diarrhea; Disease-Free Survival; Drug Therapy*; Humans; Incidence; Lymphoma; Nausea; Pemetrexed; Phosphotransferases; Vision Disorders
- From:Cancer Research and Treatment 2018;50(3):691-700
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. MATERIALS AND METHODS: This analysis evaluated previously treated and untreated patients in two randomized, open-label phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and “as-treated” populations for efficacy and safety endpoints, respectively. RESULTS: In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade)with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity. CONCLUSION: These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.
